European Journal of Cancer
Volume 39, Issue 6 , Pages 829-837 , April 2003

Study of in vitro and in vivo effects of the piperidine nitroxide Tempol—a potential new therapeutic agent for gliomas

  • M.B Gariboldi

      Affiliations

    • DBSF, Laboratory of Pharmacology, University of Insubria, Via A. da Giussano, 12, 21052 Busto Arsizio (VA), Italy
    • ,
  • R Ravizza

      Affiliations

    • DBSF, Laboratory of Pharmacology, University of Insubria, Via A. da Giussano, 12, 21052 Busto Arsizio (VA), Italy
    • ,
  • C Petterino

      Affiliations

    • Department of Public Health, Comparative Pathology and Veterinary Hygiene, Strada Romea 16, 35020 Agripolis (PD), Italy
    • ,
  • M Castagnaro

      Affiliations

    • Istituto Neurologico Besta, Via Celoria 20129 Milan, Italy
    • ,
  • G Finocchiaro

      Affiliations

    • Istituto Neurologico Besta, Via Celoria 20129 Milan, Italy
    • ,
  • E Monti

      Affiliations

    • DBSF, Laboratory of Pharmacology, University of Insubria, Via A. da Giussano, 12, 21052 Busto Arsizio (VA), Italy
    • Corresponding Author InformationCorresponding author. Tel.: +39-0331-339415; fax: +39-0331-339459

Received 3 April 2002 ,Revised 19 August 2002 ,Accepted 23 October 2002.

References 

  1. Levin VA, Gutin PH, Leibel S. Neoplasms of the central nervous system. In:  De Vita VT,  Hellman S,  Rosenberg SA editor. Cancer Principles and Practice of Oncology. Philadelphia: Lippincott; 1993;p. 1697–1737
  2. Hosli P, Sappino AP, De Tribolet N, Dietrich PY. Malignant glioma (should chemotherapy be overthrown by experimental treatments?). Ann. Oncol. 1996;9:589–600
  3. Gariboldi MB, Lucchi S, Caserini C, Supino R, Oliva C, Monti E. Antiproliferative effect of the piperidine nitroxide TEMPOL on neoplastic and nonneoplastic mammalian cell lines. Free Rad. Biol. Med. 1998;24:913–923
  4. Gariboldi MB, Rimoldi V, Supino R, Favini E, Monti E. The nitroxide TEMPOL induces oxidative stress, p21 WAF1/CIP1, and cell death in HL60 cells. Free Rad. Biol. Med. 2000;29:633–641
  5. Gomez-Manzano C, Fueyo J, Kyritsis AP, et al.  Characterization of p53 and p21 functional interactions in glioma cells en route of apoptosis. J. Natl. Cancer Inst. 1997;89:1036–1044
  6. Zhang R, Shohami E, Beit-Yannai E, Bass R, Trembovler V, Samuni A. Mechanism of brain protection by nitroxide radicals in experimental model of closed-head injury. Free Rad. Biol. Med. 1998;24:332–340
  7. Mitchell JB, Wink DA, DeGraff W, Gamson J, Keefer LK, Krishna MC. Hypoxic mammalian cells radiosensitization by nitric oxide. Cancer Res. 1993;53:5845–5848
  8. Alley MC, Scudiero DA, Monks A, et al.  Feasibility of drug screening with panels of human tumour cell lines usin a microculture tetrazolium assay. Cancer Res. 1988;48:589–601
  9. United Kingdom Co-Ordinating Committee On Cancer Research (UKCCCR) Guidelines for the welfare of animals in experimental neoplasia [second edition] Br J Cancer 1998, 77, 1–10.
  10. Assimakopoulou M, Sotiropoulou-Bonikou G, Maraziotis T, Papadakis N, Varakis I. Microvessel density in brain tumours. Anticancer Res. 1997;17:4747–4753
  11. Plate HK. Gene therapy of malignant glioma via inhibition of tumour angiogenesis. Cancer Metast. Rev. 1996;15:237–240
  12. Monti E, Cova D, Guido E, Morelli R, Oliva C. Protective effect of the nitroxide Tempol against the cardiotoxicity of adriamycin. Free Rad. Biol. Med. 1996;21:463–470
  13. Samuni A, DeGraff W, Krishna MC, Mitchell JB. Cellular sites of H2O2-induced damage and their protection by nitroxides. Biochim. Biophys. Acta. 2001;1525:70–76
  14. Suy S, Mitchell JB, Ehleiter D, Haimovitz-Friedman A, Kasid U. Nitroxides tempol and tempo induce divergent signal transduction pathways in MDA-MB 231 breast cancer cells. J. Biol. Chem. 1998;273:17871–17878
  15. Wang G, Godinger D, Aronovitch J, Samuni A. Opposing effects of nitroxide free radicals in Escherichia coli mutants deficient in DNA repair. Biochim. Biophys. Acta. 1996;1305:71–78
  16. Offer T, Russo A, Samuni A. The pro-oxidative activity of SOD and nitroxide SOD mimics. FASEB J. 2000;14:1215–1223
  17. Chin YE, Kitagawa M, Su W-CS, You Z-H, Iwamoto Y, Fu X-Y. Cell growth arrest and induction of cyclin-dependent kinase inhibitor p21waf1/cip1 mediated by STAT1. Science. 1996;272:719–722
  18. Russo T, Zambrano N, Esposito F, et al.  A p53-independent pathway for activation of WAF1/CIP1 expression following oxidative stress. J. Biol. Chem. 1995;270:29386–29391
  19. Kokunai T, Tamaki N. Relationship between expression of p21WAF1/CIP1 and radioresistance in human gliomas. Jpn. J. Cancer Res. 1999;90:638–646
  20. Kondo S, Barna BP, Kondo Y, et al.  WAF1/CIP1 increases the susceptibility of p53 non-functional malignant glioma cells to cisplatin-induced apoptosis. Oncogene. 1996;13:1279–1285
  21. Hsiao M, Tse V, Carmel J, et al.  Functional expression of human p21 (WAF1/CIP1) gene in rat glioma cells suppresses tumour growth in vivo and induces radiosensitivity. Biochem. Biophys. Res. Commun. 1997;233:329–335
  22. Baudet C, Chevalier G, Chassevent A, et al.  1,25-Dihydroxyvitamin D3 induces programmed cell death in a rat glioma cell line. J. Neurosci. Res. 1996;46:540–550
  23. Pourquier P, Montaudon D, Huet S, Larrue A, Clary A, Robert J. Doxorubicin-induced alterations of c-myc and c-jun gene expression in rat glioblastoma cells (role of c-jun in drug resistance and cell death). Biochem. Pharmacol. 1998;55:1963–1971
  24. Hahn SM, Tochner Z, Krishna CM, et al.  Tempol, a stable free radical, is a novel murine radiation protector. Cancer Res. 1992;52:1750–1753
  25. Folkman J. What is the evidence that tumours are angiogenesis dependent?. J. Natl. Cancer Inst. 1990;82:4–6
  26. Matsushita H, Morishita R, Kida I, et al.  Inhibition of growth of human vascular smooth muscle cells by overexpression of p21 gene through induction of apoptosis. Hypertension. 1998;31:493–498
  27. Paulsen F, Hoffmann W, Becker G, et al.  Chemotherapy in the treatment of recurrent glioblastoma multiforme (ifosfamide versus temozolomide). J. Cancer Res. Clin. Oncol. 1999;125:411–418
  28. O'Reilly SM, Newlands ES, Glaser MG, et al.  Temozolomide (a new oral cytotoxic chemotherapeutic agent with promising activity against primary brain tumours). Eur. J. Cancer. 1993;29A:940–942

PII: S0959-8049(02)00742-6

doi: 10.1016/S0959-8049(02)00742-6

European Journal of Cancer
Volume 39, Issue 6 , Pages 829-837 , April 2003

Article Tools

* Image Usage & Resolution